Psychiatry and Behavioral Sciences
Jacobo Mintzer, MD, MBA
Dr. Jacobo Mintzer has been involved in clinical research on Alzheimer’s disease for the last 20 years. He developed the Geriatric Psychiatry and Alzheimer’s research program at the Medical University of South Carolina in 1991. Since then, he has developed, executed, and led numerous investigator initiated clinical research programs, both as PI and as a collaborator. As PI, he recently completed ADMET (1R01AG033032-01), a study that he had the pleasure to lead a team of investigators that conceived, designed, and lead the project to success. Currently, this study has generated two publications. This phase II study generated great interest from clinicians and researchers. This interest has encouraged the ADMET team to propose a phase III trial to generate the required information that hopefully will lead to changing clinical practice for the care of patients with apathy and Alzheimer’s disease. Dr. Mintzer served as co-PI to Dr. Devanand in a clinical trial aiming to evaluate the effects of discontinuation of risperidone in patients with agitation and psychosis who responded to that treatment. This work was successfully completed and led to a recent publication in the New England Journal of Medicine. He was also PI with other leaders in Depression in Alzheimer’s Disease II (1R01AG031348-01), another project that has been successful in its conception, development, and execution. More recently, Dr. Mintzer was a co-investigator and co-author of a study published in the Journal of American Medical Association, showing that Vitamin E in high doses can slow down the progression of Alzheimer’s Disease. As a senior collaborator, Dr. Mintzer had the pleasure of being part of the Alzheimer’s Disease Cooperative Study (ADCS) Steering Committee as well as the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Steering Committee. He has been an active participant in all activities of this entity including the publications committee. In addition, Dr. Mintzer is a past president of the International Psychogeriatric Association, a Professor of the MUSC College of Health Professions, and a staff physician at the Ralph H. Johnson VA Medical Center. Lastly, he is the Executive Director of Clinical Research and the Alzheimer’s Disease Research Center, at the Clinical Biotechnology Research Institute at Roper St. Francis Healthcare System in Charleston, SC.
|At the completion of this session, the participant will be able to:|
1. Discuss the new trend of thought for the treatment of Alzheimer’s Disease.
2. Name at least two new large projects aiming to treat different symptoms of Alzheimer’s Disease.